A phase 2b, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial evaluating the efficacy and safety of dose regimens with oral tofacitinib in the treatment of subjects with moderate-to-severe chronic plaque psoriasis

Trial Profile

A phase 2b, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial evaluating the efficacy and safety of dose regimens with oral tofacitinib in the treatment of subjects with moderate-to-severe chronic plaque psoriasis

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Mar 2016 Pooled analysis (n=3431) of 5 trials [NCT00678210, NCT01276639, NCT01309737, NCT01241591, NCT01186744] were presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 02 Dec 2013 Results published in the Journal of Dermatological Treatment.
    • 25 May 2011 Pruritis results presented at the 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top